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Abstract
Protein misfolding cyclic amplification (PMCA) recapitulates the prion protein (PrP) conversion process under cell-free
conditions. PMCA was initially established with brain material and then with further simplified constituents such as partially
purified and recombinant PrP. However, availability of brain material from some species or brain material from animals with
certain mutations or polymorphisms within the PrP gene is often limited. Moreover, preparation of native PrP from
mammalian cells and tissues, as well as recombinant PrP from bacterial cells, involves time-consuming purification steps. To
establish a convenient and versatile PMCA procedure unrestricted to the availability of substrate sources, we attempted to
conduct PMCA with the lysate of cells that express cellular PrP (PrP
C). PrP
Sc was efficiently amplified with lysate of rabbit
kidney epithelial RK13 cells stably transfected with the mouse or Syrian hamster PrP gene. Furthermore, PMCA was also
successful with lysate of other established cell lines of neuronal or non-neuronal origins. Together with the data showing
that the abundance of PrP
C in cell lysate was a critical factor to drive efficient PrP
Sc amplification, our results demonstrate
that cell lysate in which PrP
C is present abundantly serves as an excellent substrate source for PMCA.
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Introduction
Conformational conversion of the a helix rich cellular prion
protein (PrP
C) to the b sheet rich scrapie prion protein (PrP
Sc)i s
the major biochemical event that characterizes prion diseases [1].
The protein-only hypothesis postulates that prion replication is
facilitated by PrP
Sc functioning as a template to convert PrP
C into
the disease-associated conformation [2]. Although PrP conversion
in cultured cells and animal models is possible, it has been quite
difficult to reproduce the process in vitro. To establish an in vitro
system that supports misfolding of PrP, a number of assays have
been devised (reviewed in [3]).
Protein misfolding cyclic amplification (PMCA) is an assay that
mimics the PrP
Sc propagation process under cell-free conditions.
This method amplifies misfolded PrP by converting PrP
C to PrP
Sc
during incubation with periodic sonication [4]. PrP
Sc generated by
PMCA is infectious in wild-type animals [5] and can be indefinitely
propagated with preserved properties of the original PrP
Sc [5–7].
PMCA recapitulates the species barrier of prion transmission [8–
11], prion strain interference [7], and de novo generation of prions
[12,13]. Furthermore, PMCA is quite useful in studying the
cofactors that influence PrP conversion [14–24], and in detecting
PrP
Sc from biological samples of humans and animals [25–37].
PMCA has contributed to a number of important perspectives
in prion biology, however, its conventional application to certain
investigations still faces a few challenging problems. One of these
problems is associated with the source of PMCA substrate. PMCA
was originally designed to use brain homogenate derived from
healthy animals that contains an excess amount of PrP
C, to which
a minute amount of prion-infected brain material, the source of
PrP
Sc, was diluted [4]. This prototypic method has evolved to use
the lipid raft fractions of the plasma membrane as the source for
PrP
C [23,38,39] because PrP conversion occurs at the caveolae-
like membrane domains of neuronal cells [40–42]. Recently, PrP
C
purified from brain tissue or cultured mammalian cells [19,43] and
recombinant PrP expressed in bacterial cells [30,44,45] have
replaced brain material for PMCA. Crude brain homogenate and
the lipid raft fractions of the membrane provide a comprehensive
set of components required for PMCA including a cofactor, while
purified PrP
C or recombinant PrP offers defined minimal
substrates. However, availability of brain material from certain
species or transgenic animals carrying the PrP gene with certain
mutations and polymorphisms is often limited. Alternatively,
preparation of the substrates by expression/purification of native
PrP
C from animal tissues and cell lines, as well as recombinant PrP
from bacterial cells, requires additional, laborious steps. Thus, it is
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18047necessary to establish a convenient alternative that overcomes
aforementioned drawbacks of the current PMCA method.
In this study, we used cell lysate of cultured mammalian cell
lines in PMCA reactions. Lysate of cultured cells has not been used
as a substrate source for PMCA and it has been considered
incapable of supporting PrP
Sc formation in PMCA unless
complemented with brain homogenate that may include a cofactor
for PrP conversion [6,46]. Based on our recent observation that
PrP
C abundance is critical for robust PrP
Sc propagation in PMCA
[21], we performed PMCA with PrP-expressing cell lysates in
which the level of PrP
C was equivalent to wild type brain material.
Here, we show that PMCA replication of mouse and hamster-
adapted PrP
Sc using cell lines that express murine and hamster
PrP
C, respectively.
Results
Estimation of the PrP
C level in cell lines
We established RK13 cells that express the full-length mouse
and Syrian hamster PrP open reading frames, designated
RK13MoPrP and RK13SHaPrP. We compared the level of PrP
C
in RK13MoPrP to that of FVB/N wild type brain homogenate
and several cell lines: N2a, SMB-PS, NIH 3T3, CRBL, and Hpl-
3-4 cells (Fig. 1A). Western blot analysis indicated that
RK13MoPrP cells expressed PrP
C at a higher level than other
PrP
C-expressing cell lines. However, the abundance of PrP
C in
RK13MoPrP cells was lower than wild type mouse brain, but
similar to RK13MoPrP-gag cells in which the retroviral gag gene
was coexpressed with mouse PrP. Among previously established
cell lines, the level of PrP
C in N2a, SMB-PS, and CRBL was
similar to each other, but greater compared to NIH 3T3. RK13,
RK13vector, and Hpl 3–4 lacked PrP
C expression. RK13SHaPrP
cells expressed PrP
C at a lower level than wild type Syrian hamster
brain.
Next, we investigated whether PrP
C expressed in our newly
established RK13 cell line colocalized to lipid rafts in the plasma
membrane as observed in nature. Immunofluorescence microsco-
py revealed that the location of PrP
C expression in RK13MoPrP
cells was at the cell surface and colocalized with the glycosphin-
golipid GM1, a marker for lipid rafts (Fig. 1B). This suggests that
PrP
C expressed in RK13MoPrP cells was processed normally and
localized as usually found in nature.
PMCA propagation of PrP
Sc is supported using
RK13MoPrP and RK13MoPrP-gag cell lysate
RK13MoPrP cell lysate was applied to PMCA for PrP
Sc
amplification. Similar levels of PrP
C from RK13MoPrP cells and
murine brain were used in PMCA (Fig. 1A). The PrP
C in
RK13MoPrP cell lysate was converted into PrP
Sc when seeded
with RML prions (Fig. 2A, top panel). This result was similar to
PMCA using wild type brain homogenate (Fig. 2A, bottom panel).
As expected, PrP
Sc of RML (Rocky Mountain Laboratory) prions
was not propagated in the absence of PrP
C when lysate of
untranfected RK13 cells was used in PMCA (Fig. 2A, second
panel). Normal brain homogenate did not induce spontaneous
PrP
Sc formation from RK13MoPrP cell lysate (Fig. 2A, third
panel). In serial PMCA, RK13MoPrP cell lysate was able to
support continuous propagation of PrP
Sc (Fig. 2B).
To investigate if PrP
C abundance in cell lysate influences
PMCA conversion of PrP
C, we conducted PMCA with
RK13MoPrP cell lysate diluted 1:10 in lysate of normal RK13
cells that do not express PrP
C. Consistent with our previous
PMCA studies with brain material [21], the amount of PrP
C
present in cell lysate dictated the level of PrP
Sc generation in
PMCA. PrP
Sc amplification with diluted RK13MoPrP cell lysate
was less efficient than amplification with undiluted substrate
(Fig. 3). Spontaneous generation of PrP
Sc in PMCA was not
observed when normal brain material was used as the seeding
source (Fig. 3).
Because expression of the human immunodeficiency virus-1
(HIV-1) gag gene in cultured cells promotes formation of PrP
Sc in
the cell culture models of prion disease [47], we assessed whether
HIV-1 Gag influences in vitro amplification of PrP
Sc. To address
this, we performed PMCA using RK13MoPrP-gag cell lysate as a
substrate and PrP
Sc from RML prions as seeds. We failed to detect
a significant difference in PrP
Sc conversion efficiency using PMCA
between RK13MoPrP-gag and RK13MoPrP cell lysates (Fig. 4),
suggesting that HIV-1 Gag does not affect PrP
Sc conversion.
Lysate of both neuronal and non-neuronal cell lines
supports PMCA generation of PrP
Sc
To assess the ability of lysate derived from previously established
cell lines to support PMCA, we prepared cell lysate in which PrP
C
was concentrated to the same level as wild type mouse brain
material (Fig. 1A). The cell lines from diverse origins were chosen:
N2a neuroblastoma cells exhibit characteristics of neurons [48];
SMB-PS cells derived from scrapie-infected mouse brain but cured
by in vitro treatment with pentosan sulfate are originated from the
mesenchymal lineage [49]; CRBL cells derived from the
cerebellum of p53 null mice show expression of both glial and
neuronal markers [50]; and NIH 3T3 cells feature the character-
istics of common fibroblasts [51]. All of the tested lysates supported
PrP
Sc propagation in PMCA (Fig. 5), suggesting that PrP
conversion is not exclusively dependent on the neuronal cells.
The efficiency of PMCA formation of PrP
Sc varies upon
the cellular source of PrP
C
We compared the efficiency of PMCA generation of PrP
Sc using
cell lysate from different sources. Based on the densitometric
analysis of the Western blots, we plotted the normalized PrP
Sc
levels of each pre- and post-PMCA sample. The PrP
Sc levels
amplified with RK13MoPrP and N2a cell lysate were greater than
those generated by wild type brain homogenate, but less than
those generated by Tg(MoPrP)4112 [21] brain homogenate
(Fig. 6A and B). The PrP
Sc levels amplified with CRBL and
NIH3T3 cell lysate were almost identical with those generated by
wild type brain homogenate (Fig. 6C). The SMB-PS cell lysate was
not obviously better than wild type brain homogenate or cell lysate
of other cell types (Fig. 6B). To further investigate the efficacy of
RK13MoPrP and N2a cell lysate in generating PrP
Sc, the fold
increase of newly synthesized PrP
Sc was plotted. The rates of PrP
Sc
generation by RK13MoPrP and N2a cell lysate were intermediate
between those obtained with Tg4112 and wild type brain
homogenate (Fig. 6D). Similar analysis for cell lysate of other cell
lines indicated that the rate of PrP
Sc formation resembled that of
wild type brain homogenate (data not shown).
PMCA propagation of PrP
Sc is supported using lysate of
RK13 cells that express Syrian hamster PrP
C
To address that cell lysate-based PMCA is not restricted to
murine PrP
C and murine-adapted scrapie prions, we performed
PMCA using Syrian hamster PrP
C and the hyper (HY) and drowsy
(DY) strains of hamster-adapted transmissible mink encephalop-
athy (TME) prions [52]. PrP
Sc from either HY or DY strains was
successfully amplified in PMCA using RK13SHaPrP cell lysate
(Fig. 7A). The strain-specific migration of HY and DY PrP
Sc was
similar between brain-derived and PMCA-generated material
Cell Lysate-Based PMCA
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DY in cell lysate-based PMCA (Fig. 7B), which corresponds to the
results of PMCA studies that used Syrian hamster brain
homogenate and bioassays of HY and DY in Syrian hamsters [7].
Discussion
The current study demonstrates that cell lysate with concen-
trated PrP
C allowed robust PMCA of PrP
Sc from multiple strains
and species. The ability of cell lysate to support PrP
Sc formation in
PMCA is comparable to that of wild type brain material. This
result suggests that cell lysate can replace animal organ-derived
material for in vitro PrP
Sc amplification without compromising PrP
conversion efficiency.
Previously, cultured cell lysate was shown to support extremely
low levels of PrP
Sc formation [46]. Moreover, PMCA with lysate
of animal cells has been reported to require compensation with
PrP
2/2 brain material for adequate amplification [6], suggesting
that additional factors derived from the brain material are
required to properly amplify PrP
Sc using cell lysate. In contrast
to these results, our study demonstrated that cell lysate is sufficient
to support PrP
Sc amplification, although inclusion of the ‘‘auxiliary
factors’’ in cell lysate remains to be elucidated. The discrepancy
between previous and current results may be due to the
abundance of PrP
C in PMCA. As opposed to the previous studies
using cell lysate with the endogenous level of PrP
C, our study
exploited cell lysate with concentrated PrP
C. As demonstrated in
our previous [21] and current studies, the abundance of PrP
C is a
critical factors to guarantee robust PrP
Sc amplification.
Our data suggest that, by adjusting PrP
C levels to wild type
brain material, lysate of newly engineered and previously
established animal cell lines can serve as an excellent substrate
for PMCA, in which PrP
C maintains its native states of subcellular
localization, conformation, glycosylation, disulfide bridging, and
glycosylphosphatidylinositol anchoring [40,42,53,54]. Since these
post-translational modification states can affect the efficiency of
PMCA [17,22], use of material that include PrP
C in its native form
localized in the lipid rafts might result in more efficient PMCA
than a similar reaction with recombinant PrP that lacks native
conformation and post-translational modifications.
Figure 1. Expression of PrP
C in a variety of cell lines. (A) Comparison of the PrP
C levels in cell lines and brain homogenate. Western blotting
followed by densitometry demonstrated relative differences of the PrP
C levels. Extrapolation of multiplication factors to concentrate cell lysate was
based on the amount of protein analyzed and the relative PrP
C levels. PrP
C was detected by D13 (left blot), 6H4 (middle blot), and 3F4 (right blot)
antibodies. (B) Fluorescence images of RK13 cells expressing full length mouse PrP
C. Colocalization (yellow, overlay) of PrP
C (green) and GM1 (red) in
the lipid rafts of the plasma membrane of RK13MoPrP was shown by confocal microscopy. The nuclei (blue) were stained by Hoechst 33258. Scale
was shown by a 30 mm bar.
doi:10.1371/journal.pone.0018047.g001
Cell Lysate-Based PMCA
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affect PrP
Sc conversion, suggesting that retroviral Gag functions in
PrP
Sc propagation through the mechanism other than the PrP
conversion process. Instead, it may play a role in the regulatory
mechanisms for prion susceptibility and maintenance of prion
infection at the cellular level as evidenced by Gag-enhanced
release of mouse-adapted scrapie from cell cultures [55].
To date, the existence of the ‘‘auxiliary factors’’ for PrP
conversion remains unknown. Recent PMCA studies showed that
conversion of purified and recombinant PrP
C to infective PrP
Sc
was successful in the absence of any cofactor [44]. In contrast,
other lines of PMCA-based investigations suggest the presence of a
cofactor for PrP conversion [14,23,24,45,56]. Some demonstrate
enhanced PrP conversion by supplementation with undefined
crude homogenate or partially purified fractions of cells and tissues
[23,39,56], while others specify RNA [14] and plasminogen [24]
for the cofactor activity. However, the tissue specific presence or
utilization of this cofactor remains to be further investigated. A
recent report proposed the existence of a brain-specific cofactor
[57], whereas other studies indicated the presence of the cofactor is
not limited to the brain. In fact, PrP conversion by PMCA is
successful with spleen and muscle tissue homogenate [58] and
PMCA with purified PrP
C is equally robust when supplemented
with tissue homogenate of major wild type organs including the
brain [23]. In agreement, our results showed that lysate of both
neuronal and non-neuronal cells supported robust PMCA
independent of the origin of the cell types. This suggests that the
cofactor for PrP conversion is unlikely to be present exclusively in
the brain or in neurons, if it exists.
Cell lysate-based PMCA may provide convenience in examin-
ing PrP conversion influenced by the PrP
C sequence variability.
PrP
C of various species or with either mutations or polymorphisms
can be expressed in the mammalian cell lines and the cell lysate
can be used for PMCA without purification. This offers a practical
alternative to using brain material of limited availability or purified
and recombinant PrP that require laborious, time-consuming
procedures for preparation.
In summary, lysate of cultured cells that express PrP
C is an
excellent substrate source to amplify PrP
Sc in PMCA. Validation
of cell lysate-based PMCA introduces a convenient model system
Figure 2. PMCA using cell lysate of RK13MoPrP and RK13. (A) Amplification of protease-resistant PrP
Sc of RML prions. The level of PK-resistant
PrP
Sc before (2) and after (+) PMCA was compared by Western blotting using monoclonal anti-PrP 6H4 antibody. Prion-sick (RML) and normal (NBH)
brain homogenate were diluted 100–24,000 fold in cell lysate (CL) of RK13MoPrP and RK13. PMCA using wild type FVB/N brain homogenate (BH) was
conducted as a control. (B). Serial PMCA with RK13MoPrP cell lysate as substrates. Initially, RML seeds were diluted 100–1,000,000 fold, and then the
products of PMCA in each round were diluted 10 fold thereafter. The PK-resistant PMCA products were detected by Western blotting using
monoclonal anti-PrP 6H4 (panel A) and 5C6 (panel B) antibodies.
doi:10.1371/journal.pone.0018047.g002
Cell Lysate-Based PMCA
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Sc amplification affected by PrP
C abundance in cell lysate. PMCA was performed using undiluted and diluted (1:10 fold)
RK13MoPrP cell lysate (CL). Both RML and NBH were used as seeds in dilutions of 100–24,000 fold. PK-treated pre- (2) and post-PMCA (+) samples
were analyzed. Western blotting was performed using monoclonal anti-PrP 6H4 antibody.
doi:10.1371/journal.pone.0018047.g003
Figure 4. Influence of Gag expression to PrP
Sc amplification. PMCA using RK13MoPrP and RK13MoPrP-gag cell lysate was conducted with
(1,800–180,000 fold diluted) or without (no seeds) RML seeds. Cell lysate of RK13vector that lacks expression of both PrP
C and Gag was used as a
control. Pre- (2) and post-PMCA (+) samples were treated with PK and analyzed by and monoclonal anti-PrP 5C6 antibody was used for Western
blotting.
doi:10.1371/journal.pone.0018047.g004
Cell Lysate-Based PMCA
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conversion associated with diverse PrP sequence variances.
Materials and Methods
Ethics statement
The experiments using animals were carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Institutional Animal
Care and Use Committee the University of Kentucky (IACUC ID
Number: 2006-0044). The procedures to establish new cell lines
were carried out based on the protocol approved by the
Institutional Biosafety Committee of the University of Kentucky
(Registration Number: B10-795).
Cell lines
The cell lines used for the study are following: a rabbit kidney
epithelial cell line RK13(ATCC, CCL37) [59]; a mouse
neuroblastoma cell line, N2a (ATCC, CCL131) [48]; a scrapie-
infected mouse brain cell line cured by pentosan sulfate, SMB-PS
[49]; a mouse fibroblast cell line, NIH3T3 (ATCC, CRL1658)
[51]; a mouse cerebellar cell line, CRBL [50]; a PrP knockout
mouse hippocampal neuronal cell line, Hpl 3–4 [60]; two RK13
cell lines that either express mouse PrP
C alone (RK13MoPrP) or
coexpress both mouse PrP
C and retroviral Gag protein
(RK13MoPrP-gag); and RK13 cells that express Syrian hamster
PrP
C (RK13SHaPrP). RK13MoPrP and RK13SHaPrP were
established by stable transfection of RK13 cells that lack
expression of endogenous PrP
C with the PrP open reading frames
of each species cloned in the mammalian expression vector
pIRESpuro3 (Clonetech, PaloAlto, CA) by the method described
previously [61]. RK13vector was established by transfection with
empty pIRESpuro3 plasmid. The stable transfectants were
obtained by selection with 1 mg/ml puromycin. RK13MoPrP-
gag was established by stably transfecting RK13MoPrP with
pcDNA3-gag that harbors the gene for HIV-1 Gag precursor
protein. RK13MoPrP-gag was selected with 1 mg/ml Geneticin
Figure 5. PMCA using lysates of a wide range of cell types. Cell lysate of neuronal (N2a), prion-free brain mesenchymal (SMB-PS), mixed
cerebellar neuronal and glial (CRBL) or fibroblast (NIH 3T3) cells was concentrated to include the PrP
C level of wild brain homogenate. PMCA was
performed by seeding with RML-sick (RML) and normal (NBH) brain homogenate. The seed dilution fold was 100–24,000. The PrP
Sc level of PMCA
before (2) and after (+) was compared. Monoclonal anti-PrP 6H4 antibody was used for Western blotting.
doi:10.1371/journal.pone.0018047.g005
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[47].
Cell culture
Culture of the cell lines were conducted as described elsewhere
[50]. Briefly, cells were grown in Dulbecco’s Modified Eagle’s
Medium (high glucose, Invitrogen) containing 10% fetal bovine
serum, 1% penicillin-streptomycin, 1% glutamax under saturated
humidity and 5% CO2 conditions at 37uC.
Fluorescence microscopy
RK13MoPrP cells cultured onto 22622 mm square glass cover
slips were fixed with 4% paraformaldehyde and blocked with 10%
goat serum (Invitrogen). For PrP staining, cells were incubated
with 0.5 mg/ml monoclonal anti-PrP primary antibody, 6H4
(1:500 dilution) (Prionics, Zurich, Switzerland) and fluorescein-
conjugated goat anti-mouse IgG secondary antibody (1:500
dilution) (Jackson ImmunoResearch Lab Inc, West Grove, PA)
for 45 min each at room temperature. For GM1 staining, cell were
Figure 6. Comparison of ability of cell lysate to support PMCA. (A–C) The levels of PrP
Sc in pre- (2, dashed line with filled symbols) and post-
PMCA (+, solid line with open symbols) samples shown in Figures 2, 3, and 4 were measured by densitometry and presented as relative % to that of
the 1:100 diluted PrP
Sc seeds (n=3 each). (D) Efficacy of PMCA supported by different PrP
C sources was presented as fold increase of the PrP
Sc level
compared to the PrP
Sc level of seeds in each dilution. The data sets for transgenic mice that overexpress PrP
C in the brain (Tg4112) was obtained from
the Western blots previously published [21].
doi:10.1371/journal.pone.0018047.g006
Cell Lysate-Based PMCA
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subunit (1:50 dilution) (Invitrogen)for 45 min. Counterstaining of
nuclei using 5 mg/ml Hoechst 33342 dye (Invitrogen) was
performed simultaneously during incubation with the secondary
antibody. The cover slips mounted on glass slides with 15 ml
Mowiol mounting medium were immediately observed via a Leica
AOBS TCS SP5 inverted laser scanning confocal microscope.
PMCA with cell lysate
PMCA was conducted by using cell derived material as the
PrP
C source. Cultured cells in the 100 mm-diameter culture plates
were washed twice with 10 ml phosphate buffered saline (PBS)
The adhered cells were harvested in 1ml PBS using a cell scraper.
Depending on the level of PrP
C in each cell line, cells in 5–15
plates were combined and centrifuged at 1,0006g for 5 min at
4uC. Pellet was washed with 10ml PBS once again before
resuspended in 1 ml PMCA conversion buffer [PBS, pH 7.2,
150 mM NaCl, 1% Trition X-100, 4 mM EDTA, 1X Comple-
teMini protease inhibitors (Roche)]. Cell lysate was made by
serially passaging through hypodermic needles from 16 to 21
gauges. After centrifugation at 2,0006g for 5 min at 4uC,
supernatant was used as the substrate for PMCA.
Brain homogenate (10% w/v) of terminally ill FVB mice
inoculated with RML prions or Syrian hamsters inoculated with
either the HY or DY TME agents was used as the source for PrP
Sc
seeds. For PMCA, the seed was diluted as indicated (10
2–10
6 fold)
in 0.1 ml cell lysate. Then, PMCA was performed as previously
described [21]. Briefly, 94 cycles of amplification was conducted at
37uC with periodic 40 s sonication every 30 min using Misonix
Model 3000 (Farmingdale, NY). For serial PMCA, the PMCA
products from previous amplification rounds were diluted 10 fold
in 0.1 ml of fresh cell lysate and subjected to repeated cycles of
amplification as described above. Total four rounds of PMCA
were carried out for the current study.
Western blot analysis
Western blotting for cell lysate to measure the expression level of
PrP
C was performed with samples not treated with PK. However,
the pre- and post-PMCA samples were treated with PK (100 mg/
ml) for 1 hr at 37uC, and then subjected to Western blotting. The
procedure followed the protocol described in the previous
publication [50]. Mouse and Syrian hamster PrP was recognized
by incubation with monoclonal anti-PrP antibodies, 6H4 (Prionics,
Zurich, Switzerland), D13 (Inpro, South San Francisco, CA), 3F4
(Signet Laboratory, Boston, MA), and 5C6 (raised against full
length recombinant cervid PrP. G. Telling, unpublished data).
Monoclonal anti-b-actin (ACTN05, Neomarker, Fremont, CA)
and anti-HIV p24 (Chemicon, Temecula, CA) antibodies were
Figure 7. PMCA using cell lysate of RK13SHaPrP. (A) PK-resistant PrP
Sc amplification of two Syrian hamster-adapted TME prions (HY and DY)
with cell lysate (CL) of RK13SHaPrP. The HY and DY seeds were diluted 100–2,500 fold for PMCA. The level of PrP
Sc in pre- (2) and post-PMCA (+)
samples was analyzed by Western blotting. (B) Comparison of the PK-resistant PrP
Sc of HY and DY prions generated by PMCA. The HY and DY seeds
were diluted 100–62,500 fold for PMCA. Ten % brain homogenate (BH) of HY- and DY-sick Syrian hamsters were used as controls. PrP
Sc in both panels
A and B was detected by monoclonal anti-PrP 3F4 antibody.
doi:10.1371/journal.pone.0018047.g007
Cell Lysate-Based PMCA
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peroxidase conjugated goat anti-mouse IgG (Pierce, Rockford, IL)
antibody was used as the secondary antibody. The signal was
developed by using the ECL plus substrate (Amersham Pharmacia,
Piscataway, NJ) and visualized by scanning with the Fuji Film FLA
5000 image reader (Fuji Film, Edison, NJ).
Doc-It Image Analysis Software (UVP, Upland, CA) was used
for densitometry analysis. Densitometry data were used to estimate
the levels of PrP
C expressed in each cell line and PrP
Sc generated
by PMCA. The level of newly generated PrP
Sc and efficiency of
PMCA was calculated as described previously [21].
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